Differentiating Superficial Thrombophlebitis from Cellulitis
Superficial thrombophlebitis presents with a palpable, cord-like, thrombosed superficial vein with localized tenderness along the vein's course, while cellulitis presents as diffuse erythema, warmth, and edema without a palpable venous cord.
Key Clinical Distinctions
Superficial Thrombophlebitis
- Palpable findings: Firm, cord-like structure following the path of a superficial vein (most commonly the great saphenous vein in 60-80% of cases) 1
- Distribution: Linear pattern along the venous tract, well-demarcated borders
- Associated features: Localized tenderness directly over the affected vein, minimal surrounding tissue involvement
- Risk factors: Varicose veins, recent IV catheter use, hypercoagulable states, malignancy 2
Cellulitis
- Palpable findings: No cord-like structure; diffuse soft tissue involvement
- Distribution: Spreading erythema with poorly defined borders, may have "peau d'orange" appearance (skin dimpling around hair follicles) 3
- Associated features: Warmth, swelling, tenderness over a broader area; may have lymphangitis (red streaking) and regional lymphadenopathy 3
- Risk factors: Skin breakdown, tinea pedis, trauma, edema, venous insufficiency 3
Critical Diagnostic Pitfall
Important caveat: Approximately 12% of patients with lower leg cellulitis have concomitant deep vein thrombosis (DVT) as an incidental finding 4. Consider duplex ultrasound in patients with cellulitis who have risk factors for thrombosis or who fail to respond to appropriate antibiotic therapy.
Treatment Recommendations
For Superficial Thrombophlebitis
Fondaparinux 2.5 mg subcutaneously daily for 45 days is the evidence-based first-line treatment for superficial thrombophlebitis at risk of progression 5. This regimen reduces:
- Symptomatic VTE by 85% (RR 0.15)
- ST extension by 92% (RR 0.08)
- ST recurrence by 79% (RR 0.21)
Alternative options if fondaparinux is unavailable or patient refuses parenteral therapy:
- Rivaroxaban 10 mg daily orally 5
- Prophylactic-dose LMWH for at least one month 6, 5
- NSAIDs (reduce extension and recurrence by ~54%) 6, 5
Adjunctive measures:
- Elastic compression stockings
- Continued ambulation (bed rest is contraindicated) 7
- Topical NSAIDs for symptom relief 6
For Cellulitis (Nonpurulent)
For typical nonpurulent cellulitis, treat with antibiotics active against streptococci for 5 days 3, 8. Extend treatment only if no improvement by day 5.
Outpatient oral options 3:
- Cephalexin 500 mg every 6 hours
- Penicillin VK
- Amoxicillin
- Dicloxacillin
- Clindamycin (if penicillin-allergic)
When to add MRSA coverage 3:
- Penetrating trauma or injection drug use
- Purulent drainage present
- Evidence of MRSA infection elsewhere
- Nasal MRSA colonization
- Systemic inflammatory response syndrome (SIRS)
- Failure to respond to β-lactam therapy
If MRSA coverage needed, add 9, 3:
- TMP-SMX 160-800 mg every 12 hours PLUS a β-lactam (for streptococcal coverage), OR
- Doxycycline 100 mg twice daily PLUS a β-lactam, OR
- Clindamycin 300-450 mg every 6-8 hours (covers both)
- Elevate affected extremity
- Examine and treat interdigital toe web abnormalities (tinea pedis, maceration)
- Address underlying edema, venous insufficiency, or eczema
When to Hospitalize
Admit patients with cellulitis who have 3, 10:
- SIRS (fever, tachycardia, hypotension)
- Altered mental status or hemodynamic instability
- Concern for deeper/necrotizing infection
- Severe immunocompromise
- Failed outpatient therapy
- Poor medication adherence anticipated
For hospitalized patients, use IV vancomycin 15 mg/kg every 12 hours (or alternatives: daptomycin, linezolid, telavancin) plus broad-spectrum coverage if severe infection 9, 10.
Key Algorithmic Approach
- Palpate for cord-like vein → Present = superficial thrombophlebitis; Absent = likely cellulitis
- Assess borders → Linear/well-demarcated = thrombophlebitis; Diffuse/spreading = cellulitis
- Check for purulence → If present with cellulitis, add MRSA coverage
- Evaluate systemic signs → If SIRS present, hospitalize and broaden coverage
- Consider imaging → Duplex ultrasound if diagnostic uncertainty or high DVT risk factors